Liver News and Research

RSS

New treatment approach may improve survival rates for certain patients with stage 4 lung cancer

A clinical trial that combined stereotactic body radiation therapy with a specific chemotherapy regimen more than doubled survival rates for certain stage 4 lung cancer patients, UT Southwestern Medical Center cancer researchers report.

2 Jan 2015

Scientists create virtual 3D model of organ prior to operation

During minimally invasive operations, a surgeon has to trust the information displayed on the screen: A virtual 3D model of the respective organ shows where a tumor is located and where sensitive vessels can be found.

31 Dec 2014

Combination of bedaquiline and verapamil reduces side effects, improves outcomes for TB patients

While an effective treatment is available for combating multidrug-resistant tuberculosis, it carries serious side effects for patients.

31 Dec 2014

Patent recognizes peptide that reduces tissue damage

A Kansas State University research team has received a patent for its use of a peptide that has been shown to prevent or reduce damage to intestinal tissue.

24 Dec 2014

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

AbbVie receives Health Canada approval for HOLKIRA PAK (ombitasvir/paritaprevir/ritonavir film-coated tablets; dasabuvir film-coated tablets), an all-oral, short-course (12 weeks for the majority of patients), interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with cirrhosis.

23 Dec 2014

Study underscores the importance of appropriate testing, support and care for HCV patients

A new study shows that many patients infected with the hepatitis C virus (HCV) are lost during different stages of health care to manage the disease.

23 Dec 2014

Medical researchers at Saint Louis University bring hope to those in pain and sickness

This year, Saint Louis University medical researchers advanced their fields, contributing to human knowledge and bringing hope to those in pain and sickness.

23 Dec 2014

Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has dosed the first patient in a Phase II trial for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

22 Dec 2014

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

The U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis.

21 Dec 2014

New analysis finds global improvements in life expectancy

Global life expectancy increased by 5.8 years in men and 6.6 years in women between 1990 and 2013, according to a major new analysis from the Global Burden of Disease Study 2013 (GBD 2013).

19 Dec 2014

New study highlights importance of generating awareness about HCV testing, support and care

A new study shows that many patients infected with the hepatitis C virus (HCV) are lost during different stages of health care to manage the disease. This real-life' view of the HCV patient care continuum in a major U.S. urban area is published in Hepatology, a journal of the American Association for the Study of Liver Diseases, and highlights the importance of generating awareness among clinicians and at-risk groups about appropriate HCV testing, referral, support and care.

18 Dec 2014

R. Geigy Foundation recognizes scientific endeavours in neglected disease research, public health

The R. Geigy Foundation honours two scientific endeavours in neglected disease research and public health. It confers the R. Geigy Award (10'000 CHF) to the Laotian scientists Somphou Sayasone and the Jubilee Award (70'000) to the project "Connecting the Dots" proposed by the Swiss Tropical and Public Health Institute.

18 Dec 2014

Study provides new evidence for anti-cirrhotic effects of GENFIT's GFT505

GENFIT, a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces that a recent study provides new evidence for anti-cirrhotic effects of GFT505 in the context of NASH.

17 Dec 2014

Centenary researchers find potential way to stop spread of tumors

By blocking a widespread enzyme, Centenary researchers have shown they can slow down the movement of cells and potentially stop tumours from spreading and growing.

16 Dec 2014

Molecular signaling pathways in the gut influence NAFLD

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder and affects approximately 1 billion people worldwide. It is not clear how this disease develops, but recent studies suggest that the bacterial population in the gut influences NAFLD.

15 Dec 2014

ETH Zurich, University of Zurich jointly open new translational research centre

ETH Zurich and the University of Zurich are taking their long-standing partnership to a new level with a new translational research centre. The two universities are founding the Wyss Translational Center Zurich (WTZ) with funds donated by Hansjörg Wyss to the ETH Zurich Foundation.

14 Dec 2014

HEPscreen Toolkit seeks to raise awareness on chronic viral hepatitis in Europe

A new toolkit on screening for chronic viral hepatitis seeks to raise awareness, improve knowledge and motivate public health professionals in Europe to take action. Knowledge and understanding of what works in screening for chronic hepatitis B/C has now been translated into practical and relevant tools, including videos and animations, to enable others to replicate successful screening programmes among at risk populations in their area.

14 Dec 2014

New study eliminates hepatitis C virus as causative factor of mental impairment in HIV patients

Advances in treatment for human immunodeficiency virus (HIV) have made it possible for people with HIV to survive much longer. As they age, however, many experience impaired thinking, memory loss, mood swings and other evidence of impaired mental function.

14 Dec 2014

New study helps identify public health needs relating to HIV/AIDS, hepatitis C in Massachusetts

A new study from epidemiologists at Tufts University School of Medicine helps to identify communities with the greatest public health need in Massachusetts for resources relating to HIV/AIDS and hepatitis C.

14 Dec 2014

New study finds that immune cells in the brain may contribute to obesity

Immune cells perform a previously unsuspected role in the brain that may contribute to obesity, according to a new study by UC San Francisco researchers.

14 Dec 2014

Liver News and Research

New treatment approach may improve survival rates for certain patients with stage 4 lung cancer

Scientists create virtual 3D model of organ prior to operation

Combination of bedaquiline and verapamil reduces side effects, improves outcomes for TB patients

Patent recognizes peptide that reduces tissue damage

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

Study underscores the importance of appropriate testing, support and care for HCV patients

Medical researchers at Saint Louis University bring hope to those in pain and sickness

Can-Fite BioPharma begins dosing in CF102 Phase II liver cancer trial

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

New analysis finds global improvements in life expectancy

New study highlights importance of generating awareness about HCV testing, support and care

R. Geigy Foundation recognizes scientific endeavours in neglected disease research, public health

Study provides new evidence for anti-cirrhotic effects of GENFIT's GFT505

Centenary researchers find potential way to stop spread of tumors

Molecular signaling pathways in the gut influence NAFLD

ETH Zurich, University of Zurich jointly open new translational research centre

HEPscreen Toolkit seeks to raise awareness on chronic viral hepatitis in Europe

New study eliminates hepatitis C virus as causative factor of mental impairment in HIV patients

New study helps identify public health needs relating to HIV/AIDS, hepatitis C in Massachusetts

New study finds that immune cells in the brain may contribute to obesity

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News